methyl 5-(4-methylphenoxy)pyrazine-2-carboxylate

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: methyl 5-(4-methylphenoxy)pyrazine-2-carboxylate
• 英文别名: Methyl 5-(4-methylphenoxyl)pyrazine-2-carboxylate
• 化学式: C₁₃H₁₂N₂O₃
• mdl: MFCD32186601
• 分子量: 244.25
• InChiKey: YJLUEAWFHUJTKP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.153
• 拓扑面积：
  61.3
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  methyl 5-(4-methylphenoxy)pyrazine-2-carboxylate 在 二异丁基氢化铝 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 0.5h， 以1.10 g的产率得到5-(4-methylphenoxy)pyrazine-2-carbaldehyde
  参考文献：
  名称：

  PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND

  摘要：

  公开号：

  EP2881384B1
• 作为产物：
  描述：

  对甲酚 、 5-氯吡嗪-2-羧酸甲酯 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.17h， 以1.36 g的产率得到methyl 5-(4-methylphenoxy)pyrazine-2-carboxylate
  参考文献：
  名称：

  PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND

  摘要：

  公开号：

  EP2881384B1

文献信息

• 4-Pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament
  申请人：Boehringer Ingelheim International GmbH

  公开号：US20200121691A1

  公开（公告）日：2020-04-23

  Disclosed are 4-pyrazin-2-ylmethyl-morpholines of formula A and pharmaceutically acceptable salts thereof, wherein R 1 and R 2 are defined herein. Also disclosed are processes for their preparation, pharmaceutical compositions containing the compounds, and their use in therapy, particularly in the treatment or prevention of conditions having an association with NR2B negative allosteric modulating properties.

  揭示了具有A式的4-吡嗪-2-甲基-吗啉及其药用盐，其中R1和R2如本文所定义。还揭示了它们的制备方法，含有这些化合物的药物组合物，以及它们在治疗中的应用，特别是在与NR2B负向变构调节性质相关的疾病的治疗或预防中。
• Partially saturated nitrogen-containing heterocyclic compound
  申请人：TAISHO PHARMACEUTICAL CO., LTD

  公开号：US09422240B2

  公开（公告）日：2016-08-23

  There are provided compounds having a superior PHD2 inhibitory effect that are represented by general formula (I′): (in the above-mentioned general formula (I′), W, Y, R2, R3, R4, and Y4 are as described hereinabove), or pharmaceutically acceptable salts thereof.

  提供了具有优越的PHD2抑制效果的化合物，其通式表示为(I'):(在上述通式(I')中，W、Y、R2、R3、R4和Y4如上所述)，或其药学上可接受的盐。
• 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament
  申请人：Boehringer Ingelheim International GmbH

  公开号：US11166958B2

  公开（公告）日：2021-11-09

  Disclosed are 4-pyrazin-2-ylmethyl-morpholines of formula A and pharmaceutically acceptable salts thereof, wherein R1 and R2 are defined herein. Also disclosed are processes for their preparation, pharmaceutical compositions containing the compounds, and their use in therapy, particularly in the treatment or prevention of conditions having an association with NR2B negative allosteric modulating properties.

  公开了式 A 的 4-吡嗪-2-基甲基吗啉 及其药学上可接受的盐类，其中 R1 和 R2 在本文中定义。此外，还公开了其制备工艺、含有这些化合物的药物组合物及其在治疗中的用途，特别是在治疗或预防与 NR2B 负性异构调节特性有关的疾病中的用途。
• US9422240B2
  申请人：——

  公开号：US9422240B2

  公开（公告）日：2016-08-23
• [EN] 4-PYRAZIN-2-YLMETHYL-MORPHOLINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT<br/>[FR] DÉRIVÉS DE 4-PYRAZIN-2-YLMÉTHYL-MORPHOLINE ET LEUR UTILISATION EN TANT QUE MÉDICAMENT
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2020079039A1

  公开（公告）日：2020-04-23

  The present invention relates to novel 4-pyrazin-2-ylmethyl-morpholines of general formula A, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an asso- ciation with NR2B negative allosteric modulating properties.